Literature DB >> 1648494

Imidazoline-guanidinium and alpha 2-adrenergic binding sites in basolateral membranes from human kidney.

V Lachaud-Pettiti1, R A Podevin, Y Chrétien, A Parini.   

Abstract

In the present study, we used [3H]idazoxan and [3H]rauwolscine to characterize the imidazoline-guanidinium receptive site (IGRS) and alpha 2-adrenoceptors in the human renal proximal tubule, respectively. In purified basolateral membranes, 11-fold enriched in Na(+)-K+ ATPase. [3H]idazoxan and [3H]rauwolscine binding was twofold higher than in homogenates ([3H]idazoxan: 87 +/- 19 vs. 45 +/- 23.3 fmol/mg protein, P less than 0.05; [3H]rauwolscine: 56.4 +/- 21.4 vs. 25.2 +/- 7.3 fmol/mg protein, P less than 0.01). In competition studies performed at saturating concentration of [3H]idazoxan (15 NM), specific binding was competed for by epinephrine and rauwolscine only by 10-15% but was completely inhibited by imidazoline and guanidinium compounds. Thus, in human renal proximal tubule. [3H]idazoxan mainly binds to an IGRS. The highest density of alpha 2-adrenoceptors in basolateral membranes and of IGRS in partially purified membrane preparations, suggests that these two binding sites have a different subcellular localization. When compared to the rabbit renal IGRS, the human [3H]idazoxan binding site displays different affinities for guanabenz, rilmenidine, clonidine, amiloride and its derivatives that persist after membrane solubilization. In contrast, the human and rabbit renal IGRS share similar regulatory properties such as the sensitivity to K+ and the insensitivity to Na+, divalent cations and 5'-guanylylimidodiphosphate (Gpp(NH)p). In conclusion, we demonstrated that, in the human renal proximal tubule, alpha 2-adrenoceptors are mainly located in basolateral membranes while IGRS appear to be associated with another cell compartment. As indicated by their common interaction with imidazoline and guanidinium derivatives and by similar regulatory properties, human and rabbit IGRS belong to the same family of membrane proteins.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648494     DOI: 10.1016/0922-4106(91)90142-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery.

Authors:  G J Molderings; F Hentrich; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

2.  Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alpha2-adrenoceptors.

Authors:  B Sjöholm; J Lähdesmäki; K Pyykkö; M Hillilä; M Scheinin
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Dose-effect relationship of rilmenidine after chronic administration.

Authors:  R Luccioni; M Lambert; P Ambrosi; M Scemama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1- and I2-imidazoline binding sites.

Authors:  G J Molderings; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

5.  Species-selective binding of [3H]-idazoxan to alpha 2-adrenoceptors and non-adrenoceptor, imidazoline binding sites in the central nervous system.

Authors:  J F Hussain; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

6.  Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

Authors:  N J Mallard; A L Hudson; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

7.  Effects of imidazolines on noradrenaline release in rat isolated kidney.

Authors:  C Bohmann; P Schollmeyer; L C Rump
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

8.  Evidence that the novel imidazoline compound FT005 is an alpha(2)-adrenoceptor agonist.

Authors:  Scott Slough; Gerald Guillaumet; Peter V Taberner
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  [3H]idazoxan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I2-imidazoline sites.

Authors:  G J Molderings; L Kundt; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

10.  Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man.

Authors:  A Wiecek; D Fliser; M Nowicki; E Ritz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.